## Published on 01 January 1991. Downloaded by University of California - Irvine on 26/10/2014 18:27:20

## Stereocontrolled Synthesis of (2*S*, 3*S*, 8*S*, 9*S*)-3-Amino-9-methoxy-2,6,8-trimethyl-10phenyldeca-4*E*,6*E*-dienoic Acid (ADDA),<sup>1</sup> the Characteristic Amino Acid of Microcystins and Nodularin

## Mark F. Beatty,\* Clive Jennings-White and Mitchell A. Avery

Bio-organic Chemistry Laboratory, Life Sciences Division, SRI International, 333 Ravenswood Avenue, Menlo Park, California 94025, USA

(4*R*,5*S*)-4-Methyl-5-phenyloxazolidin-2-one was used as a chiral template to construct the 8*S* and 9*S* chiral centres of (2*S*,3*S*,8*S*,9*S*)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid (ADDA), the 2*S* and 3*S* centres were derived from D-aspartic acid.

A number of potent hepatotoxins produced by cyanobacteria have been reported in the literature in recent years. Examples include the heptapeptide microcystin-LR<sup>1,2</sup> **1** from *Microcystis aeruginosa* and the pentapeptide nodularin<sup>1</sup> from *Nodularia spumigena*. Both closely related peptides contain the unique  $C_{20}$  amino acid (2*S*,3*S*,8*S*,9*S*)-3-amino-9-methoxy-2,6,8trimethyl-10-phenyldeca-4,6-dienoic acid<sup>1</sup> (ADDA, **2**).

It has been suggested that the hepatotoxicity of these cyclic peptides may be due to the presence of the ADDA moiety.<sup>1,3</sup> In this paper we report an efficient, stereocontrolled total synthesis of Boc-ADDA (Boc = butoxycarbonyl) and ADDA itself (as its trifluoroacetate salt), which will allow for its production in multigram quantities for hepatotoxic studies and for the synthesis of its parent peptides. Although parts of the synthesis are similar to that previously reported by Rinehart,<sup>1b</sup> the chiral centres at positions 8 and 9 are prepared in a stereocontrolled manner and thus do not require the use of HPLC to separate unwanted diastereoisomers.

For controlling the chirality at positions 8 and 9 of ADDA, we used Evans'<sup>4</sup> chiral oxazolidine template methodology as shown in Scheme 1. Thus, straightforward *N*-acylation of the oxazolidone **3** with propionyl chloride furnished the propionyl oxazolidine **4**. Enolisation of **4** with di-n-butylboron trifluromethanesulphonate and trialkylamine followed by aldol condensation with phenylacetaldehyde provided the alcohol **5** having both 2'-methyl and 3'-hydroxy chiral centres of the desired configuration. *O*-Methylation of **5** using trimethyloxonium tetrafluoroborate in the presence of 1,8-bis(dimethylamino)naphthalene (proton sponge) produced the methyl ether **6**, which was cleaved using lithium borohydride to yield the enantiomerically pure alcohol **7**. The recovered oxazlidone **3** was isolated and recycled.

Oxidation of the alcohol 7 with pyridine–sulphur trioxide in dimethyl sulphoxide (DMSO) gave the aldehyde 8, which then

underwent Wittig reaction with 1-ethoxycarbonylethylidenetriphenylphosphorane. The resultant E/Z mixture of unsaturated esters 9–10, obtained in a 4.5:1 (*trans:cis*) ratio, was reduced using diisobutylaluminium hydride (DIBAL-H) to afford alcohols 11–12. The dominant regioisomer was shown to have the *E* configuration (*trans*) by dynamic nuclear Overhauser enhancement (DNOE) experiments.† This mixture of alcohols was most conveniently carried on and separated at a later stage.



† The alkenic proton appearing at  $\delta$  5.34 of the mixture **11–12** was irradiated, resulting in 6% enhancement of the hydroxymethylene peak occurring at  $\delta$  4.0 of the major isomer.



Scheme 1. Reagents and conditions: i, 1.6 mol dm<sup>-3</sup> Bu<sup>n</sup>Li in hexanes, tetrahydrofuran (THF), -78 °C, 30 min; ii, EtCOCl, -78 °C to room temp. 2 h; iii, Bu<sup>n</sup><sub>2</sub>BOSO<sub>2</sub>CF<sub>3</sub> (1.1 equiv.), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; iv, Pr<sup>i</sup><sub>2</sub>EtN (1.2 equiv.), 0 °C, 30 min; v, PhCh<sub>2</sub>CHO (1.1 equiv.), -78 °C, 30 min, then room temp. for 1.5 h; vi, Me<sub>3</sub>O<sup>+</sup>BF<sub>4</sub><sup>-</sup>, proton sponge (1.16 equiv.), CH<sub>2</sub>Cl<sub>2</sub>, 7 days; vii, LiBH<sub>4</sub> (2 equiv.), 16h; viii, pyridine. SO<sub>3</sub> (3.0 equiv.), DMSO, 30 min; ix, Ph<sub>3</sub>P=C(Me)CO<sub>2</sub>Et (1.05 equiv.), dimethylformamide (DMF), 6 days; x, DIBAL-H (11.0 equiv.), -78 °C for 2 h, then room temp. overnight; xi, PPh<sub>3</sub> (2 equiv.), CBr<sub>4</sub> (2 equiv.), Et<sub>2</sub>O, 7 h; xii, PPh<sub>3</sub>, benzene, reflux, 6 h; xiii, 1.6 mol dm<sup>-3</sup> Bu<sup>n</sup>Li in hexanes, THF, 0 °C, 10 min; xiv, **21** (0.9 equiv.), THF, 0 °C, 3 h.; xv, aq. NH<sub>4</sub>Cl; xvi, 1 mol dm<sup>-3</sup> NaOH (2 equiv.), MeOH, 4 days; xvii, CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, 30 min. All reactions at room temperature unless indicated otherwise.

Next, the aldehyde 21 was synthesized as shown in Scheme 2. Dianion alkylation of methyl ester 17 to give the desired *erythro* diastereoisomer 18 proved to be somewhat troublesome. If the alkylation of dianion derived from 17 was carried out at -78 °C, the product ratio consisted of 96% unwanted *threo* diastereoisomer along with only 4% of the desired *erythro*-isomer 18. However, by forming the dianion of 17 at -78 °C and then allowing it to react with methyl iodide at -7 °C, a product ratio of 43% *erythro* 18 and 57% *threo* could be obtained. Next, hydrogenolysis of 18 furnished the acid 19, which was then reduced by borane in THF (while carefully



Scheme 2. Reagents and conditions: i, lithium hexamethyldisilazide (2.0 equiv.), THF, -78 °C, 1 h; ii, MeI (1.2 equiv.), -7 °C, 1 h; iii aq. NH<sub>4</sub>Cl-ice; iv, H<sub>2</sub>/Pd, MeOH, 2 h; v, BH<sub>3</sub>·THF (3.0 equiv.), 0 °C, 1 h; vi, pyridine–SO<sub>3</sub> (3.0 equiv.), DMSO, Et<sub>3</sub>N (3.0 equiv.), room temp. 30 min

monitoring the reaction by TLC) to give the stable alcohol **20**. Mild oxidation of this alcohol was conveniently accomplished in DMSO with pyridine–sulphur trioxide in the presence of triethylamine, yielding the desired aldehyde **21**.

The mixture of alcohols 11-12 was converted to the corresponding bromides and thence to the triphenylphosphonium salts 13-14. The ylide derived from 13-14 was treated with the protected aldehyde 21, to give a mixture of the four possible geometric isomers. The mixture was readily separated by preparative TLC to give the desired isomer 15, taking care to avoid possible photochemical isomerization. Hydrolysis of 15 with dilute sodium hydroxide in methanol gave Boc-ADDA  $16,\ddagger\$$  which, on treatment with trifluoroacetic acid, gave ADDA 2 as its trifluoroacetate.\$ The overall yield for the twelve-step synthesis of ADDA was 2.1%.

This work was supported by the US Army Medical Research and Development Command under Contract No. DAMD 17-88-C-8095. We thank Dr Robert Wannemacher of the US Army Medical Research Institute of Infectious Diseases, and Drs K. L. Rinehart and M. Namikoshi of the University of Illinois at Urbana-Champaign for spectroscopic date.

Received, 3rd October 1990; Com. 0/04470I

## References

- (a) K. L. Rinehart, K.-I. Harada, M. Namikoshi, C. Chen, C. Harvis, M. H. G. Munro, J. W. Blunt, P. E. Mulligan, V. R. Beasley, A. M. Dahlem and W. W. Carmichael, J. Am. Chem. Soc., 1988, 110, 8557; (b) K. L. Rinehart, M. Namikoshi, A. M. Dahlem, V. R. Beasley and W. W. Carmichael, Tetrahedron Lett., 1989, 30, 4349.
- 2 H. Konst, P. D. McKercher, P. R. Gorham, A. Robertson and J. Howell, *Can. J. Comp. Med. Vet. Sci.*, 1965, **29**, 221.
- 3 T. K. Chakraborty and S. P. Joshi, *Tetrahedron Lett.*, 1990, 31, 2043.
- 4 D. A. Evans and J. Bartroli, Tetrahedron Lett., 1982, 23, 807.

 $\ddagger$  The Boc-ADDA 16 was obtained as an oil:  $[\alpha]_D{}^{22}$  –15.1° (c 0.1, CHCl\_3).

§ Structure confirmed by 400 MHz <sup>1</sup>H NMR spectroscopy, and electron impact, chemical ionization and high resolution electron impact mass spectrometry.